Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas

@article{Dalloglio2008DoseintensityTA,
  title={Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas},
  author={Stefano Dall'oglio and A D'Amico and Fabio Pioli and Milena Gabbani and Felice Pasini and Maria Grazia Passarin and Andrea Talacchi and Sergio Turazzi and Sergio Maluta},
  journal={Journal of Neuro-Oncology},
  year={2008},
  volume={90},
  pages={315-319}
}
Purpose We performed a new phase II trial enrolling patients with newly diagnosed high-grade glioma (HGG) to test the efficacy of a weekly alternating temozolomide (TMZ) schedule after surgery and concomitant chemoradiotherapy. Methods From January 2005 to January 2007, 34 patients (21 men, 13 women; age range 30–70, mean age 53) were enrolled. There were 32 glioblastoma multiforme and two anaplastic astrocytoma. Each patient after surgery received standard concurrent chemoradiotherapy. After a… 
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
TLDR
The dose-dense temozolomide regimen was well tolerated, although it has no significant activity in this population of patients, and there were trends towards longer PFS and OS with MGMT promoter methylation.
Chemopotentiation by Ultrafractionated Radiotherapy in Glioblastoma Resistant to Conventional Therapy
TLDR
This modified regimen resulted in regression of the contrast-enhancing areas of disease recurrence identified on MRI, and the patient survived approximately 6 months following recurrence of her disease, having received 5 cycles of additional therapy after prior full-dose treatment.
Chemotherapy in glioma.
TLDR
The current standard of treatment for diffuse gliomas is described in this overview and in addition some attention is given to targeted therapies.
Phase II rial of 7 days on / 7 days off temozolmide for recurrent high-grade glioma
TLDR
An exploratory objective included the investigation of whether methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter within tumor tissue predicted outcomes.
PrACTiC: A Predictive Algorithm for Chemoradiotherapy-Induced Cytopenia in Glioblastoma Patients
TLDR
The algorithm designed and developed in this study, called PrACTiC, showed promising results in the accurate prediction of thrombocytopenia, neutropania, and lymphopenia induced by TMZ in glioblastoma patients.
Unmet needs in the treatment of glioblastoma
TLDR
Several controversies and unmet needs in the diagnosis and treatment of Glioblastoma multiforme are discussed.
On the Concepts and History of Glioblastoma Multiforme - Morphology, Genetics and Epigenetics
TLDR
With the introduction of molecular and genetic tests the true multifomity of GBM has been established, with different genotypes bearing the same histomorphological and IHC picture, as well as some of the aspects of gliomagenesis.
Advances in drug delivery technology for the treatment of glioblastoma multiforme.
...
...

References

SHOWING 1-10 OF 17 REFERENCES
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
TLDR
The prolonged temozolomide schedule considered in the present study is followed by a high response rate; toxicity is acceptable; further randomized trials should therefore be conducted to confirm the efficacy of this regimen as first-line therapy in patients with progressive low grade glioma.
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
  • A. Wick, J. Felsberg, W. Wick
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Preliminary evidence is provided that this dose-dense schedule of temozolomide administered 1 week on and 1 week off is also active in patients with tumors lacking MGMT gene promoter methylation, and may be less toxic.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
TLDR
The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
A phase II study of temozolomide administered 21 out of 28 days for the treatment of patients with recurrent anaplastic (oligo)astrocytoma: An interim analysis of toxicity
TLDR
The toxicity that was associated with this regimen at the occasion of the first interim monitoring of the adverse events was reported, and extended daily dosing of TMZ might be more active because of the depletion of the AGAT repair protein.
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
TLDR
The prolonged temozolomide schedule considered in the present study is followed by a high PFS-6 rate; toxicity is acceptable and further randomised trials should be conducted to confirm the efficacy of this regimen.
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
TLDR
This dose-dense temozolomide regimen resulted in modest antitumor activity with an acceptable safety profile in the neoadjuvant setting, and expression of MGMT correlated with response to temozalomide.
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
TLDR
When given orally once daily for 5 days, temozolomide was well tolerated and produced a non-cumulative, transient myelosuppression, the most common non-haematological toxicities were mild to moderate nausea and vomiting.
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
  • E. Wong, K. Hess, W. Yung
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Histology is a dominant factor in determining outcome in patients with recurrent glioma enrolled onto phase II chemotherapy trials and future trials should be designed with separate histology strata.
Methylguanine methyltransferase testing in glioblastoma: when and how?
  • R. Stupp, M. Hegi
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Methylation of the MGMT gene promoter has been found to be a predictive marker for benefit from TMZ treatment in patients treated with temozolomide chemotherapy, and patients without MGMT promoter methylation should not be treated with alkylating agent chemotherapy.
...
...